Skip to main content

Table 4 Relative gene expression of the 15 genes comprising the pre-treatment signature comparing responders in the discovery dataset to healthy volunteers and to non-responders

From: Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

15-Gene Pre-Treatment Model

Predictor or Enhancer Variable

Blood Bank

Difference Normals versus Responders

Phase 3 Discovery Dataset

 

N = 50

N = 28

N = 182

Difference

Healthy Normals

Responders

Non-Responders

Responders vs Non-responders

Responders Equivalent to Normals

 ITGA4

Predictor

14.2

0.02

14.22

14.61

0.39

 LARGE

Predictor

22.0

0.09

22.09

22.97

0.88

 CDK2

Predictor

19.6

0.09

19.69

19.91

0.22

 TIMP1

Enhancer

15.0

0.10

15.1

14.95

−0.15

 DPP4

Predictor

18.5

0.12

18.62

18.95

0.33

 NRAS

Predictor

17.1

0.13

17.23

17.44

0.21

 ERBB2

Predictor

23.0

−0.18

22.82

23.23

0.41

 NAB2

Predictor

20.0

−0.29

19.71

20.04

0.33

Responders Upregulated Compared to Normals

 ADAM17

Enhancer

18.5

0.32

18.18

18.36

0.18

 RHOC

Enhancer

16.9

0.39

16.51

16.63

0.12

 TGFB1

Enhancer

13.4

0.45

12.95

13.05

0.10

 CDKN2A

Predictor

21.4

0.63

20.77

21.16

0.39

Responders Downregulated Compared to Normals

 HLADRA

Enhancer

12.1

0.48

12.58

12.64

0.06

 MYC

Enhancer

17.7

0.82

18.53

18.67

0.14

Measurement of Gene Expression Not Available

 ICOS

Predictor

N/A

N/A

22.32

22.78

0.46